SCHEMBL4082987

SCHEMBL4082987

CS(=O)(=O)c1cc(CCC(=O)OCC(O)CO)nc(-c2nc(=O)c3ccc(Cl)cc3s2)c1

nearest known ligand 0.31

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.31
MAPK1 P28482 2/20 0.31
HSD17B10 Q99714 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MLNR O43193 1/20 0.31
ABCB11 O95342 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CHRM2 P08172 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
CHRM1 P11229 1/20 0.31
GABRA1 P14867 1/20 0.31
HPGD P15428 1/20 0.31
TBXA2R P21731 1/20 0.31
PTGS1 P23219 1/20 0.31
SLC6A2 P23975 1/20 0.31
PDE4A P27815 1/20 0.31
ADORA2A P29274 1/20 0.31
ADRA1A P35348 1/20 0.31
PTGS2 P35354 1/20 0.31
OPRM1 P35372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13940269 0.93 MCL1 (0.31) KDM4E
SCHEMBL4085450 0.88 KDM4E (0.36) CYP3A4MAPK1HSD17B10KDM4EALDH1A1
SCHEMBL4087175 0.87 CASP3 (0.34) HSD17B10KDM4EALDH1A1
SCHEMBL4082600 0.86 EGFR (0.38) KDM4EPTGS2
SCHEMBL4094700 0.84 POLB (0.33) KDM4E
SCHEMBL4092707 0.84 MAPT (0.33) HSD17B10KDM4EALDH1A1HPGDPTGS2
SCHEMBL4094643 0.84 HDAC6 (0.42)
SCHEMBL4082720 0.83 HTT (0.39) MAPK1KDM4E
Potassium Ion SCHEMBL4088703 0.82 MEN1 (0.33) KDM4EALDH1A1
SCHEMBL4093006 0.82 MEN1 (0.33) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029975-A1 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029975-A1 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF MIF, CCL2, MSR1 CYP3A4 1771/4885MAPK1 838/4885HSD17B10 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.